Editas Medicine Inc (EDIT)
2.44
+0.07
(+2.95%)
USD |
NASDAQ |
Nov 22, 16:00
2.435
0.00 (0.00%)
After-Hours: 20:00
Editas Medicine Cash from Investing (Quarterly): 83.98M for Sept. 30, 2024
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 83.98M |
| June 30, 2024 | 51.95M |
| March 31, 2024 | -4.745M |
| December 31, 2023 | 62.84M |
| September 30, 2023 | -102.82M |
| June 30, 2023 | 12.98M |
| March 31, 2023 | 23.27M |
| December 31, 2022 | -27.53M |
| September 30, 2022 | 89.23M |
| June 30, 2022 | -4.002M |
| March 31, 2022 | 56.37M |
| December 31, 2021 | -22.84M |
| September 30, 2021 | -39.66M |
| June 30, 2021 | 4.791M |
| March 31, 2021 | 3.244M |
| December 31, 2020 | -108.89M |
| September 30, 2020 | -152.26M |
| June 30, 2020 | 74.17M |
| March 31, 2020 | 46.46M |
| December 31, 2019 | 7.818M |
| Date | Value |
|---|---|
| September 30, 2019 | -122.30M |
| June 30, 2019 | 76.11M |
| March 31, 2019 | 50.63M |
| December 31, 2018 | -8.604M |
| September 30, 2018 | -13.62M |
| June 30, 2018 | -71.68M |
| March 31, 2018 | 40.82M |
| December 31, 2017 | 26.68M |
| September 30, 2017 | -28.85M |
| June 30, 2017 | -180.98M |
| March 31, 2017 | -0.656M |
| December 31, 2016 | 0.963M |
| September 30, 2016 | -0.713M |
| June 30, 2016 | -1.161M |
| March 31, 2016 | -2.562M |
| December 31, 2015 | -0.401M |
| September 30, 2015 | -0.19M |
| June 30, 2015 | -0.535M |
| March 31, 2015 | -0.305M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-152.26M
Minimum
Sep 2020
89.23M
Maximum
Sep 2022
2.718M
Average
6.304M
Median
Cash from Investing (Quarterly) Benchmarks
| Ionis Pharmaceuticals Inc | -340.80M |
| EyePoint Pharmaceuticals Inc | 16.20M |
| Cassava Sciences Inc | -0.017M |
| Adverum Biotechnologies Inc | -13.35M |
| Regenxbio Inc | 50.26M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -52.59M |
| Free Cash Flow | -191.36M |
| Free Cash Flow Per Share (Quarterly) | -0.673 |
| Free Cash Flow to Equity (Quarterly) | -55.51M |
| Free Cash Flow Yield | -95.49% |